Soligenix Q1 2025 Earnings Report

Soligenix EPS Results

• Actual EPS: -$1.06
• Consensus EPS: -$0.67
• Beat/Miss: Missed by -$0.39
• One Year Ago EPS: N/A

Soligenix Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Soligenix Announcement Details

• Quarter: Q1 2025
• Date: 5/9/2025
• Time: Before Market Opens
• Conference Call Date: Thursday, May 8, 2025
• Conference Call Time: 7:00PM ET

Soligenix (NASDAQ:SNGX), Inc. is a clinical‐stage biopharmaceutical company focused on developing vaccines and therapeutics to address unmet medical needs in rare diseases and biodefense. The company leverages proprietary technologies to create novel vaccine adjuvants, small‐molecule innate defense regulators and photodynamic therapies aimed at improving patient outcomes in orphan indications and protecting public health against biological threats.

The company’s pipeline is organized into two core divisions. In its Biodefense division, Soligenix is advancing vaccine candidates and antitoxins for agents such as ricin and anthrax, utilizing its RiVax platform and specialized formulation systems to enhance immunogenicity and stability. Within its Orphan Drug division, the lead candidates include SGX942 (dusquetide), an innate defense regulator in late‐stage development for the prevention and treatment of oral mucositis in head and neck cancer patients, and SGX301 (synthetic hypericin), a photodynamic therapy designed for the treatment of cutaneous T‐cell lymphoma.

Soligenix employs collaborations and funding agreements with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA) and the National Institutes of Health (NIH), to support its biodefense programs and accelerate clinical development. The company’s technology platforms enable the delivery of targeted immune modulation and improved safety profiles, positioning its candidates for both civilian and military medical countermeasure applications.

Founded in 2004 and headquartered in Princeton, New Jersey, Soligenix operates primarily within the United States. The executive leadership team is led by President and Chief Executive Officer Christopher J. Schaber, who brings extensive experience in guiding clinical development and forging strategic partnerships. Soligenix remains committed to advancing its portfolio of specialized therapies and vaccines to serve underserved patient populations and bolster national biosecurity preparedness.